Comparative Pharmacology
Head-to-head clinical analysis: D H E 45 versus TRIAD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: D H E 45 versus TRIAD.
D.H.E. 45 vs TRIAD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydroergotamine (DHE) is a semi-synthetic ergot alkaloid that acts as an agonist at serotonin (5-HT1B/1D) receptors, causing vasoconstriction of intracranial blood vessels and inhibition of trigeminal nerve transmission, thereby aborting migraine attacks. It also has high affinity for alpha-adrenergic receptors and moderate affinity for dopamine D2 receptors.
Triad is a combination of three antibiotics: amoxicillin, metronidazole, and tetracycline. Amoxicillin inhibits bacterial cell wall synthesis. Metronidazole disrupts bacterial DNA synthesis via reduction to toxic metabolites. Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
1 mg intramuscularly or subcutaneously at first sign of headache, repeat hourly up to 3 mg per day, maximum 6 mg per week.
Not applicable. TRIAD is not a recognized drug; no standard dosing exists.
None Documented
None Documented
2.5 hours (range 2-3.5 hours) for ergotamine; clinical context: short half-life supports its use in acute migraine, but frequent dosing risks ergotism.
Terminal t1/2 = 12–15 hours; prolonged to 24–36 hours in hepatic impairment.
Primarily hepatic metabolism; renal excretion of metabolites accounts for approximately 90% of elimination, with 10% fecal.
Renal: 30% unchanged; Biliary/fecal: 70% as metabolites.
Category C
Category C
Antimigraine Agent
Antimigraine Agent